21.5 C
New York
Saturday, June 3, 2023

The Question Is Whether To Buy Or Not To Buy Humanigen Inc. (NASDAQ: HGEN)

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Humanigen Inc. (HGEN) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0043, or 2.87%, to $0.1543. The Humanigen Inc. has recorded 4,606 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Humanigen – Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia.

Unlock the Hottest Top 10 Penny Stocks Today! Discover Now

Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.

Gain Access to Top 10 Penny Stocks Now!.


Stocks Info

Humanigen Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.15 and fluctuated between $0.1583 as its day high and $0.1493 as its day low. The current market capitalization of Humanigen Inc. is $18.89M. A total of 1.0 million shares were traded on the day, compared to an average of 1.42M shares.

Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, HGEN has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 6 BUYs and 0 SELLs from insiders. Insiders purchased 869,296 shares during that period but sold 0.

In the most recent transaction, Chappell Dale bought 545,488 shares of HGEN for 2.23 per share on May 20. After the transaction, the Chief Scientific Officer now owns 8,675,081 company shares.

Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for HGEN in the last 3 months, the mean price target is $0.33 with high estimates of $0.50 and low estimates of $0.15. In terms of 52-week highs and lows, HGEN has a high of $3.25 and a low of $0.09.

As of this writing, HGEN has an earnings estimate of -$0.06 per share for the current quarter. EPS was calculated based on a consensus of 1 estimates, with a high estimate of -$0.06 per share and a lower estimate of -$0.06. The company reported an EPS of -$0.23 in the last quarter, which was -27.80% lower than expectations of -$0.18.

Balance Sheet Annually/Quarterly

A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. HGEN’s latest balance sheet shows that the firm has $70.02M in Cash & Short Term Investments as of fiscal 2021. There were $25.01M in debt and $68.72M in liabilities at the time. Its Book Value Per Share was -$0.39, while its Total Shareholder’s Equity was -$23.69M.

Analysts Opinion

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HGEN is Buy with a score of 3.00.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles